March 20, 2026 · Form 4 insider transaction
Prasad Raju bought 38,499 shares of CRISPR Therapeutics AG at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.; This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.